The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Retinal Drugs and Biologics Market Research Report 2024

Global Retinal Drugs and Biologics Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1889620

No of Pages : 91

Synopsis
The global Retinal Drugs and Biologics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Retinal Drugs and Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Retinal Drugs and Biologics.
Report Scope
The Retinal Drugs and Biologics market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Retinal Drugs and Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Retinal Drugs and Biologics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
ALLERGAN
AbbVie
Alimera Sciences
Janssen Biotech
Swedish Orphan Biovitrum
Roche
Bristol-Myers Squibb
Genzyme
Genentech
OCULAR THERAPEUTIX
Bausch & Lomb
UCBCares
Segment by Type
Age Related Macular Degeneration
Diabetic Retinopathy
Ocular Inflammatory Disease (Uveitis)
Macular Hole
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Retinal Drugs and Biologics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Retinal Drugs and Biologics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Retinal Drugs and Biologics Market Overview
1.1 Product Overview and Scope of Retinal Drugs and Biologics
1.2 Retinal Drugs and Biologics Segment by Type
1.2.1 Global Retinal Drugs and Biologics Market Value Comparison by Type (2024-2030)
1.2.2 Age Related Macular Degeneration
1.2.3 Diabetic Retinopathy
1.2.4 Ocular Inflammatory Disease (Uveitis)
1.2.5 Macular Hole
1.3 Retinal Drugs and Biologics Segment by Application
1.3.1 Global Retinal Drugs and Biologics Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Retinal Drugs and Biologics Market Size Estimates and Forecasts
1.4.1 Global Retinal Drugs and Biologics Revenue 2019-2030
1.4.2 Global Retinal Drugs and Biologics Sales 2019-2030
1.4.3 Global Retinal Drugs and Biologics Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Retinal Drugs and Biologics Market Competition by Manufacturers
2.1 Global Retinal Drugs and Biologics Sales Market Share by Manufacturers (2019-2024)
2.2 Global Retinal Drugs and Biologics Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Retinal Drugs and Biologics Average Price by Manufacturers (2019-2024)
2.4 Global Retinal Drugs and Biologics Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Retinal Drugs and Biologics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Retinal Drugs and Biologics, Product Type & Application
2.7 Retinal Drugs and Biologics Market Competitive Situation and Trends
2.7.1 Retinal Drugs and Biologics Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Retinal Drugs and Biologics Players Market Share by Revenue
2.7.3 Global Retinal Drugs and Biologics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Retinal Drugs and Biologics Retrospective Market Scenario by Region
3.1 Global Retinal Drugs and Biologics Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Retinal Drugs and Biologics Global Retinal Drugs and Biologics Sales by Region: 2019-2030
3.2.1 Global Retinal Drugs and Biologics Sales by Region: 2019-2024
3.2.2 Global Retinal Drugs and Biologics Sales by Region: 2025-2030
3.3 Global Retinal Drugs and Biologics Global Retinal Drugs and Biologics Revenue by Region: 2019-2030
3.3.1 Global Retinal Drugs and Biologics Revenue by Region: 2019-2024
3.3.2 Global Retinal Drugs and Biologics Revenue by Region: 2025-2030
3.4 North America Retinal Drugs and Biologics Market Facts & Figures by Country
3.4.1 North America Retinal Drugs and Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Retinal Drugs and Biologics Sales by Country (2019-2030)
3.4.3 North America Retinal Drugs and Biologics Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Retinal Drugs and Biologics Market Facts & Figures by Country
3.5.1 Europe Retinal Drugs and Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Retinal Drugs and Biologics Sales by Country (2019-2030)
3.5.3 Europe Retinal Drugs and Biologics Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Retinal Drugs and Biologics Market Facts & Figures by Country
3.6.1 Asia Pacific Retinal Drugs and Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Retinal Drugs and Biologics Sales by Country (2019-2030)
3.6.3 Asia Pacific Retinal Drugs and Biologics Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Retinal Drugs and Biologics Market Facts & Figures by Country
3.7.1 Latin America Retinal Drugs and Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Retinal Drugs and Biologics Sales by Country (2019-2030)
3.7.3 Latin America Retinal Drugs and Biologics Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Retinal Drugs and Biologics Market Facts & Figures by Country
3.8.1 Middle East and Africa Retinal Drugs and Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Retinal Drugs and Biologics Sales by Country (2019-2030)
3.8.3 Middle East and Africa Retinal Drugs and Biologics Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Retinal Drugs and Biologics Sales by Type (2019-2030)
4.1.1 Global Retinal Drugs and Biologics Sales by Type (2019-2024)
4.1.2 Global Retinal Drugs and Biologics Sales by Type (2025-2030)
4.1.3 Global Retinal Drugs and Biologics Sales Market Share by Type (2019-2030)
4.2 Global Retinal Drugs and Biologics Revenue by Type (2019-2030)
4.2.1 Global Retinal Drugs and Biologics Revenue by Type (2019-2024)
4.2.2 Global Retinal Drugs and Biologics Revenue by Type (2025-2030)
4.2.3 Global Retinal Drugs and Biologics Revenue Market Share by Type (2019-2030)
4.3 Global Retinal Drugs and Biologics Price by Type (2019-2030)
5 Segment by Application
5.1 Global Retinal Drugs and Biologics Sales by Application (2019-2030)
5.1.1 Global Retinal Drugs and Biologics Sales by Application (2019-2024)
5.1.2 Global Retinal Drugs and Biologics Sales by Application (2025-2030)
5.1.3 Global Retinal Drugs and Biologics Sales Market Share by Application (2019-2030)
5.2 Global Retinal Drugs and Biologics Revenue by Application (2019-2030)
5.2.1 Global Retinal Drugs and Biologics Revenue by Application (2019-2024)
5.2.2 Global Retinal Drugs and Biologics Revenue by Application (2025-2030)
5.2.3 Global Retinal Drugs and Biologics Revenue Market Share by Application (2019-2030)
5.3 Global Retinal Drugs and Biologics Price by Application (2019-2030)
6 Key Companies Profiled
6.1 ALLERGAN
6.1.1 ALLERGAN Corporation Information
6.1.2 ALLERGAN Description and Business Overview
6.1.3 ALLERGAN Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.1.4 ALLERGAN Retinal Drugs and Biologics Product Portfolio
6.1.5 ALLERGAN Recent Developments/Updates
6.2 AbbVie
6.2.1 AbbVie Corporation Information
6.2.2 AbbVie Description and Business Overview
6.2.3 AbbVie Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AbbVie Retinal Drugs and Biologics Product Portfolio
6.2.5 AbbVie Recent Developments/Updates
6.3 Alimera Sciences
6.3.1 Alimera Sciences Corporation Information
6.3.2 Alimera Sciences Description and Business Overview
6.3.3 Alimera Sciences Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Alimera Sciences Retinal Drugs and Biologics Product Portfolio
6.3.5 Alimera Sciences Recent Developments/Updates
6.4 Janssen Biotech
6.4.1 Janssen Biotech Corporation Information
6.4.2 Janssen Biotech Description and Business Overview
6.4.3 Janssen Biotech Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Janssen Biotech Retinal Drugs and Biologics Product Portfolio
6.4.5 Janssen Biotech Recent Developments/Updates
6.5 Swedish Orphan Biovitrum
6.5.1 Swedish Orphan Biovitrum Corporation Information
6.5.2 Swedish Orphan Biovitrum Description and Business Overview
6.5.3 Swedish Orphan Biovitrum Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Swedish Orphan Biovitrum Retinal Drugs and Biologics Product Portfolio
6.5.5 Swedish Orphan Biovitrum Recent Developments/Updates
6.6 Roche
6.6.1 Roche Corporation Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Roche Retinal Drugs and Biologics Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bristol-Myers Squibb Retinal Drugs and Biologics Product Portfolio
6.7.5 Bristol-Myers Squibb Recent Developments/Updates
6.8 Genzyme
6.8.1 Genzyme Corporation Information
6.8.2 Genzyme Description and Business Overview
6.8.3 Genzyme Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Genzyme Retinal Drugs and Biologics Product Portfolio
6.8.5 Genzyme Recent Developments/Updates
6.9 Genentech
6.9.1 Genentech Corporation Information
6.9.2 Genentech Description and Business Overview
6.9.3 Genentech Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Genentech Retinal Drugs and Biologics Product Portfolio
6.9.5 Genentech Recent Developments/Updates
6.10 OCULAR THERAPEUTIX
6.10.1 OCULAR THERAPEUTIX Corporation Information
6.10.2 OCULAR THERAPEUTIX Description and Business Overview
6.10.3 OCULAR THERAPEUTIX Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.10.4 OCULAR THERAPEUTIX Retinal Drugs and Biologics Product Portfolio
6.10.5 OCULAR THERAPEUTIX Recent Developments/Updates
6.11 Bausch & Lomb
6.11.1 Bausch & Lomb Corporation Information
6.11.2 Bausch & Lomb Retinal Drugs and Biologics Description and Business Overview
6.11.3 Bausch & Lomb Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Bausch & Lomb Retinal Drugs and Biologics Product Portfolio
6.11.5 Bausch & Lomb Recent Developments/Updates
6.12 UCBCares
6.12.1 UCBCares Corporation Information
6.12.2 UCBCares Retinal Drugs and Biologics Description and Business Overview
6.12.3 UCBCares Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.12.4 UCBCares Retinal Drugs and Biologics Product Portfolio
6.12.5 UCBCares Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Retinal Drugs and Biologics Industry Chain Analysis
7.2 Retinal Drugs and Biologics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Retinal Drugs and Biologics Production Mode & Process
7.4 Retinal Drugs and Biologics Sales and Marketing
7.4.1 Retinal Drugs and Biologics Sales Channels
7.4.2 Retinal Drugs and Biologics Distributors
7.5 Retinal Drugs and Biologics Customers
8 Retinal Drugs and Biologics Market Dynamics
8.1 Retinal Drugs and Biologics Industry Trends
8.2 Retinal Drugs and Biologics Market Drivers
8.3 Retinal Drugs and Biologics Market Challenges
8.4 Retinal Drugs and Biologics Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’